Hematopathology provides a broad range of special hematology and specialized anatomic pathology testing. The department houses nationally and internationally known experts who provide consultative services and test result interpretation. To submit cases for a hematopathology consultation, refer to Consultation, Hematopathology.

Existing ARUP Clients

All submissions require an ARUP Anatomic Pathology Test Request Form, which includes an ARUP client number. For test details, view specimen requirements in the Laboratory Test Directory. If you don't have a test request form, please contact ARUP Client Services at (800) 522-2787.

For additional technical details, please contact Anatomic Pathology directly at
(800) 348-2787. Please have your ARUP client number ready when you call.

Current Non-Clients of ARUP Laboratories

Please contact Client Services at (800) 522-2787 for ordering and submission information.

• Archana Mishra Agarwal, MD
  Medical Director, Hemoglobin Laboratory
• David W. Bahler, MD, PhD
  Medical Director, Hematologic Flow Cytometry Laboratory
• Albert Ho, MD, PhD
  Co-Medical Director, Molecular Hematopathology
• Todd Kelley, MD
  Co-Medical Director, Molecular Hematopathology
• Carl R. Kjeldsberg, MD
  Consultant, Hematopathology
• Rodney R. Miles, MD, PhD
  Staff Hematopahologist
  Assistant Medical Director, Immunohistochemistry Laboratory
• Sherrie L. Perkins, MD, PhD
  Medical Director, Hematopathology Laboratory
  Chief Medical Officer and Director of Laboratories
• Mohamed E. Salama, MD
  Assistant Medical Director, Hematopathology
• Kristi J. Smock, MD
  Assistant Medical Director, Hemostasis/Thrombosis Laboratory
• Ronald L. Weiss, MD, MBA
  Staff Hematopathologist

• Bahler DW, Hartung L, Hill S, Bowen GM, Vonderheid EC. CD158k/KIR3D2L is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry. Clin Cytom 2008;74(3):156–62.
• Bahler DW, Szankasi P, Kulkarni S, Tubbs RR, Cook JR, Swerdlow SH. Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. Mod Pathol 2009;22(6):833–8.
• Szankasi P, Bahler DW. Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. J Mol Diagn 2010; 12(2):244–49.
• Ho AK, Hill S, Preobrazhensky SN, Miller ME, Chen Z, Bahler DW. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias. Am J Clin Path 2009;131(1):27–32.
• Kelley TW, Parker CJ. CD4(+)CD25(+)Foxp3(+) regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed) 2010;2:980–92.
• Efimova OV, Kelley TW. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway.
  BMC Immunol 2009;10:59.
• Kelley TW, Baz R, Hussein M, Karafa M, Cook JR. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol 2009;40(3):405–12.
• Miles RR, Afify Z, Yaish H, Perkins SL. CD56-negative extranodal nasal type NK/T-cell lymphoma. Pediatr Blood Cancer 2010;55(1):186–9.
• Miles RR, Mankey CC, Seiler CE, III, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS, Lim MS. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol 2009;40(12):1731–7.
• Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL. SFOP/LMB96/CCG5961/UKCCSG/NHL 9600 Study Group. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer 2008;51(3):369–74.
• Chang CC, Perkins SL. Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematop 2009;2:20–6.
• Hussong JW, Arber DA, Bradley KT, Brown MS, Chang C, de Baca ME, Ellis DW, Foucar K, Hsi ED, Jaffe ES, Lill M, McClure SP, Medeiros LJ, Perkins SL. Protocol for the examination of specimens from patients with non-Hodgkin lymphoma/lymphoid neoplasms. Arch Pathol Lab Med 2010;134(6):e40–7.
• Teman CJ, Wilson AR, Perkins SL, Hickman K, Prchal JT, Salama ME. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res 2010;34(7):871–6.
• Salama ME, Lossos IS, Warnke RA, Natkunam Y. Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma: a study of 51 cases. Am J Clin Pathol 2009;132(1):39–49.
• Salama ME, Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL. The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. Int J Surg Pathol 2010;18(2):121–8.
• Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman CM. Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood Coagul Fibrinolysis 2010;21(3):279–82.
• Penmetsa GK, Rodgers GM, Smock KJ. Avoiding errors in the laboratory evaluation of potent lupus anticoagulants. Am J Hematol 2010;85(4):272–4.
• Smock KJ, Rodgers GM. Laboratory identification of lupus anticoagulants. Am J Hematol 2009;84(7):440–2.
• Practical diagnosis of hematologic disorders, 5th ed. CR Kjeldsberg and SL Perkins, eds. 2010; Chicago: ASCP Press.